Reacción #1605835

ord-218fe1e14185492984f2870112c42049

Ecuación de reacción

O=C1CCc2ccc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)cc2N1
aripiprazole
O=C(Cl)N(Cc1ccccc1)Cc1ccccc1
dibenzylcarbamoyl chloride
CC1CCCO1
2-methyltetrahydrofuran
O=C(OC1=Nc2cc(OCCCCN3CCN(c4cccc(Cl)c4Cl)CC3)ccc2CC1)N(Cc1ccccc1)Cc1ccccc1
7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-3,4-dihydroquinolin-2-yl dibenzylcarbamate

Condiciones de reacción

Condiciones detalladas
See reaction.notes.procedure_details.

Tratamiento posterior

  1. 1
    Temperaturawas heated
  2. 2
    Temperaturaat reflux for 4 days
  3. 3
    TemperaturaThe reaction mixture was cooled
  4. 4
    Filtraciónfiltered through celite
  5. 5
    OtroThe organic phase was separated
  6. 6
    Secadodried over MgSO4
  7. 7
    Otroevaporated
  8. 8
    OtroThe residue obtained
  9. 9
    Otrowas further purified on silica eluting with ethyl acetate/tetrahydrofuran
  10. 10
    Otroto give
  11. 11
    Otroafter evaporation of the major product
  12. 12
    workup.ADDITIONcontaining fractions, Compound-80 (1.02 g)

Procedimiento

A mixture of aripiprazole (1.5 g, 3.3 mmol), dibenzylcarbamoyl chloride (1.74 g, 6.7 mmol) silver carbonate (3.75 g, 13.4 mmol) and 2-methyltetrahydrofuran (30 mL) was heated at reflux for 4 days. The reaction mixture was cooled, diluted with ethyl acetate and water, and then filtered through celite. The organic phase was separated, dried over MgSO4 and evaporated. The residue obtained was further purified on silica eluting with ethyl acetate/tetrahydrofuran to give after evaporation of the major product containing fractions, Compound-80 (1.02 g) was a yellow oil.

Fuente

DOI: 10.6084/m9.figshare.5104873.v1Patente: US09072788B2uspto-grants-2015_07